Background: Early prediction of poor outcomes (PO) is of great significance to the improvement of the longterm prognosis of children with a diagnosis of severe community-acquired pneumonia (SCAP).The study aimed to explore the risk factors for PO of SCAP in children. We further aimed to develop and validate a PO-predictive nomogram model for SCAP in children. Methods: A population-based, retrospective case-control study was conducted in children with a diagnosis of SCAP who were hospitalized in our hospital from August 1, 2018 to October 31, 2021. Based on the occurrence of poor outcomes (PO), children were divided into PO and the non-PO groups. The multivariate logistic regression model was used to construct the nomogram model. Results: A total of 300 children with a diagnosis of SCAP were included, and 56 children had PO. The results of multivariate logistic regression analysis revealed that the possible independent risk factors for PO were comorbidity and invasive mechanical ventilation (IMV). In internal validation, the model displayed good discrimination with a C-index of 0.866 (95% CI: 0.772~0.960) and high quality of calibration plots in the nomogram model was noted. Conclusions: The nomogram model presented good discrimination and calibration in estimating the risk of PO among pediatric patients with a diagnosis of SCAP.
Objective: To compare the real-world efficacy and safety of Biapenem and Meropenem for treating severe community-acquired pneumonia (SCAP) in children.Methods: We retrospectively evaluated 915 children with SCAP who were treated with Biapenem or Meropenem from August 2018 to June 2022. A 1:1 propensity score matching (PSM) analysis was used to reduce the actual baseline difference between groups.Results: 416 patients participated in the analysis after PSM (Biapenem: Meropenem = 1:1). For the Biapenem group and Meropenem group, the effective rates were 90.4% and 90.9%, respectively (p = 1.0) and the incidence of adverse reactions were 7.7% and 7.2%, respectively (p = 1.0). There were no statistical differences between Biapenem and Meropenem.Conclusion: In general, the efficacy and safety of Biapenem are comparable to Meropenem in the treatment of children with SCAP.